SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.3355

Change

-0.02 (-4.36)%

Market Cap

N/A

Volume

0.84M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-20 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc

+5.08 (+1.71%)

USD 148.05B
SNY Sanofi ADR

+0.33 (+0.61%)

USD 135.22B
GILD Gilead Sciences Inc

-0.08 (-0.07%)

USD 121.14B
BIIB Biogen Inc

+3.56 (+2.60%)

USD 20.97B
GRFS Grifols SA ADR

-0.08 (-1.06%)

USD 7.13B
AMRN Amarin Corporation PLC

N/A

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.01 (-0.90%)

USD 0.02B
SCLXW Scilex Holding Company

-0.01 (-6.22%)

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.32% 20% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.32% 20% F 14% F
Trailing 12 Months  
Capital Gain -80.72% 10% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.72% 10% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -38.15% 11% F 3% F
Dividend Return -38.15% 11% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.11% 33% F 53% F
Risk Adjusted Return -105.64% 11% F 3% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector